Race, ethnicity, and the efficacy of rosuvastatin in primary prevention: The Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) trial

American Heart Journal

Volumn 162, Issue 1, 2011, Pages

  Albert, Michelle A ^a   Glynn, Robert J ^a   Fonseca, Francisco A H ^b   Lorenzatti, Alberto J ^c   Ferdinand, Keith C ^d   MacFadyen, Jean G ^a   Ridker, Paul M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c HOSPITAL PRIVADO   (Argentina)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; C REACTIVE PROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; ROSUVASTATIN; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CAUCASIAN; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; ETHNICITY; FEMALE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HISPANIC; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; MYOPATHY; NEGRO; PRIMARY PREVENTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SIDE EFFECT; STROKE; TRIACYLGLYCEROL BLOOD LEVEL; UNSTABLE ANGINA PECTORIS;

EID: 79960188562     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2011.03.032     Document Type: Article

References (25)

1. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) Final Report Circulation 106 2002 3143 3421
2. Shepherd J., Cobbe S.M., and Ford I.F. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia NEJM 333 1995 1301 1307
3. Downs J.R., Clearfield M., Weis S. for the AFCAPS/TexCAPS Research Group Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels JAMA 279 1998 1615 1622 (Pubitemid 28248586)
4. Ridker P.M., Danielson E., Fonesca F.A. for the JUPITER Trial Study Group Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein NEJM 359 2008 2195 2207
5. Glynn R.J., Danielson E., and Fonseca F.A. A randomized trial of rosuvastatin in the prevention of venous thromboembolism NEJM 360 2009 1851 1861
6. Ridker P.M., Fonesca F.A., and Genest J. Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein Am J Cardiol 100 2007 1659 1664 (Pubitemid 350122337)
7. Albert M.A., Glynn R.G., and Buring J. C-reactive protein levels among women of various ethnic groups living in the United States (from the women's health study) Am J Cardiol 93 2004 1238 1242 (Pubitemid 38595677)
8. Kushiro T., Mizuno K., and Nakaya N. Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese Study Group. Pravastatin for cardiovascular event primary prevention in patients with mild-to-moderate hypertension in the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese (MEGA) Study Hypertension 53 2009 135 141
9. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic hypertensive patients randomized to pravastatin vs. usual care: the Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT) JAMA 288 2002 2998 3007
10. Lloyd-Jones D., Adams R., and Carnethon M. Heart disease and stroke statistics 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee Circulation 119 2009 480 486
11. Tang W., Detrano R.C., and Brezden O.S. Racial differences in coronary calcium prevalence among high-risk adults Am J Cardiol 75 1995 1088 1091
12. McClelland R.L., Chung H., and Detrano R. Distribution of coronary artery calcium by race, gender, and age: results from the Multi-Ethnic Study of Atherosclerosis (MESA) Circulation 113 2006 30 37 (Pubitemid 43958485)
13. Reeves M.J., Gargano J.W., Luo Z. for the Paul Coverdell National Acute Stroke Registry Michigan Prototype Investigators Effect of pretreatment with statins on ischemic stroke outcomes Stroke 39 2008 1779 1785
14. Clark L.T., Maki K.C., and Galant R. Ethnic differences in achievement of cholesterol treatment goals. Results from the national cholesterol education program evaluation project utilizing novel E-technology II J Gen Intern Med 21 2006 320 326
15. Yood M.U., McCarthy B.D., and Kempf J. Racial differences in reaching target low-density lipoprotein goal among individuals treated with prescription statin therapy Am Heart J 152 2006 777 784 (Pubitemid 44396880)
16. Simon J.A., Lin F., and Hulley S.B. Phenotypic predictors of response to simvastatin therapy among African-American and Caucasians: the Cholesterol and Pharmacogenetics (CAP) Study Am J Cardiol 97 2006 843 850
17. Ferdinand K.C., Clark L.T., and Watson K.E. Comparison of efficacy and safety of rosuvastatin versus atorvastatin in African-American patients in a six week trial Am J Cardiol 10 2006 96 100
18. Lloret R., Ycas J., and Stein M. Comparison of rosuvastatin versus atorvastatin in Hispanic-Americans with hypercholesterolemia (from the STARSHIP trial) Am J Cardiol 98 2006 768 773 (Pubitemid 44301011)
19. Krauss R.M., Mangravite L.M., and Smith J.D. Variation in the 3-hydroxyl-3-methylglutaryl coenzyme a reductase gene is associated with racial differences in low-density lipoprotein cholesterol response to simvastatin treatment Circulation 117 2008 1537 1544 (Pubitemid 351440642)
20. Chien K.L., Wang K.C., and Chen Y.C. Common sequence variants in pharmacodynamic and pharmacokinetic pathway-related genes conferring LDL cholesterol response to statins Pharmacogenomics 11 2010 309 317
21. Ho R.H., Choi L., and Lee W. Effect of drug transporter genotypes on pravastatin disposition in European and African-American participants Pharmacogenet Genomics 17 2007 647 656 (Pubitemid 47057714)
22. Khera A., McGuire D.K., and Murphy S.A. Race and gender differences in C-reactive protein levels Am J Cardiol 46 2005 464 469 (Pubitemid 41040287)
23. Hu G., Jousilahti P., and Qiao Q. The gender-specific impact of diabetes and myocardial infarction at baseline and during follow-up on mortality from all causes and coronary heart disease J Am Coll Cardiol 45 2005 1413 1418 (Pubitemid 40615611)
24. Martins D., Tareen N., and Ogedegbe G. The relative risk of cardiovascular death among racial and ethnic minorities with metabolic syndrome: data from NHANES-II mortality follow-up J Natl Med Assoc 100 2008 565 571 (Pubitemid 351717370)
25. Sattar N., Preiss D., and Murray H.M. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials Lancet 373 2010 735 742